Canada Markets closed
  • S&P/TSX

    20,154.54
    -335.82 (-1.64%)
     
  • S&P 500

    4,357.73
    -75.26 (-1.70%)
     
  • DOW

    33,970.47
    -614.41 (-1.78%)
     
  • CAD/USD

    0.7819
    +0.0013 (+0.1642%)
     
  • CRUDE OIL

    70.98
    +0.69 (+0.98%)
     
  • BTC-CAD

    57,188.25
    -4,747.43 (-7.67%)
     
  • CMC Crypto 200

    1,072.05
    -62.33 (-5.49%)
     
  • GOLD FUTURES

    1,763.40
    -0.40 (-0.02%)
     
  • RUSSELL 2000

    2,182.20
    -54.67 (-2.44%)
     
  • 10-Yr Bond

    1.3090
    -0.0610 (-4.45%)
     
  • VOLATILITY

    25.71
    +4.90 (+23.55%)
     
  • FTSE

    6,903.91
    -59.73 (-0.86%)
     
  • NIKKEI 225

    29,898.57
    -601.48 (-1.97%)
     
  • CAD/EUR

    0.6663
    +0.0015 (+0.23%)
     

Neuronetics to Present at the Canaccord Genuity 41st Annual Growth Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

MALVERN, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that Keith Sullivan, President and Chief Executive Officer, and Steve Furlong, Senior Vice President, Chief Financial Officer, and Treasurer, will participate in the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021. The Company is scheduled to present at the conference at 9:30 am Eastern Time the same day via webcast.

A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.neuronetics.com. A replay of the webcast will be archived on the website for approximately 90 days.

About Neuronetics
Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Our first commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. NeuroStar is also available in other parts of the world, including Japan, where it is listed under Japan’s national health insurance. Additional information can be found at www.neuronetics.com.

Investor Contact:
Mike Vallie or Mark Klausner
Westwicke Partners
443-213-0499
ir@neuronetics.com

Media Contact:
EvolveMKD
646.517.4220
NeuroStar@evolvemkd.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting